Compare JDZG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JDZG | ATNM |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 45.2M |
| IPO Year | 2024 | N/A |
| Metric | JDZG | ATNM |
|---|---|---|
| Price | $1.71 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 413.3K | 134.0K |
| Earning Date | 12-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,680,742.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.19 | 11.11 |
| 52 Week Low | $0.73 | $1.03 |
| 52 Week High | $7.92 | $2.41 |
| Indicator | JDZG | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 41.07 |
| Support Level | $1.10 | $1.27 |
| Resistance Level | $1.85 | $1.38 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 79.45 | 10.03 |
Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.